Matinas Biopharma
MTNB
Matinas Biopharma (MTNB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Maxim Group | Downgraded | Buy → Hold | — | Oct 31, 2024 |
| BTIG | Maintained | Buy | $3.00 | Oct 11, 2023 |
Frequently asked questions
What is the latest analyst rating on MTNB?
On Oct 31, 2024, Maxim Group downgraded Matinas Biopharma to Hold.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.